Recolony AG
Edit

Recolony AG

https://www.recolony.ch/
Last activity: 21.02.2023
Categories: BioTechCauseDataDevelopmentHumanProduct
Colorectal cancer (CRC) is the third most prevalent cancer and the second leading cause of cancer mortality worldwide. In advanced stages, 5-year-survival rates are below 15%. Based on human CRC patient data, we identified specific bacteria that are less abundant in CRC patients compared to healthy individuals. When applied orally to mice carrying CRC tumors, we could induce a potent anti-tumor response and treat those tumors successfully. We aim to develop a live biotherapeutic product based on the lyophilized form of these bacterial strains in a gastro-resistant capsules. Now, we are addressing the regulatory requirements needed for preclinical/clinical development. In 2025, we plan to perform our first-in-human clinical trial in the USZ with CRC patients to test safety and tolerability.
Mentions
5

Investors 2

Mentions in press and media 5

DateTitleDescriptionSource
21.02.2023Recolony to bring its immunotherapy into pre-clinical phase Recolony was co-founded by Ana Montalban-Arques (CEO), Philipp Busenhart (CBO), Eglė Katkevičiūtė ...startuptic...
07.11.2022InnoBooster accelerates four new projects During the next one and a half years, the selected InnoBooster projects will each receive CHF 150’...startuptic...
21.07.2022Ten Biotech startups brace for Boston Boston is a hotspot for the biotech sector, boasting over 550 companies operating in the area. The...startuptic...
15.07.2022CHF 40,000 for a microbial-based therapy for Colorectal canc...Recolony: a microbial-based therapy for Colorectal cancer Colorectal cancer (CRC) is the 3rd most p...venturekic...
28.04.2022Startups developing a new gas compression machine based on s...Beyond Scroll: a new gas compression machine based on scroll technology Compressors are key compone...venturekic...

Reviews 0

Sign up to leave a review

Sign up Log In